White House and other officials affirmed their confidence in the US Food and Drug Administration and the Centers for Disease Control and Prevention after the agencies caused a stir by recommending a pause in administration of the Janssen Biotech Inc. coronavirus vaccine because of concerns about rare blood clots.
FDA and CDC officials announced 13 April that six cases of cerebral venous sinus thrombosis in combination with thrombocytopenia had been seen a few days after the J&J shot had been administered in women age 18 to 48